secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001437749-25-013227
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals submits NDA for ET-600 (desmopressin oral solution) for central diabetes insipidus
--------------------------------------------------------------------------------

- FDA NDA submission for ET-600, a proprietary oral solution of desmopressin for central diabetes insipidus.
- Expected 10-month FDA review; potential approval and launch in Q1 2026.
- Patent expires in 2044; bioequivalence study in 75 subjects demonstrated PK equivalence to reference product.
- Estimated 3,000 pediatric patients in the U.S. with central diabetes insipidus.
- Pre-launch commercial activities underway; CEO cites strong physician demand for titratable pediatric dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925013227/0001437749-25-013227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925013227/eton20250326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-013227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer